Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Accelerated Approval Review Asks If Reg Gives De Facto Exclusivity

Executive Summary

FDA's reassessment of its accelerated approval regulations includes consideration of whether the current rule creates a de facto market exclusivity that discourages research
Advertisement

Related Content

FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
Iressa User Fee Date Pushed To May; Will Advisory Cmte. Take Second Look?
Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Accelerated Approval Standards Will Be Advisory Committee Topic In March
Advertisement
UsernamePublicRestriction

Register

PS041123

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel